minimal Common Oncology Data Elements (mCODE) Implementation Guide
3.0.0-ballot - 2023May United States of America flag

This page is part of the HL7 FHIR Implementation Guide: minimal Common Oncology Data Elements (mCODE) Release 1 - US Realm | STU1 (v3.0.0-ballot: STU 3 Ballot 1) based on FHIR R4. The current version which supercedes this version is 2.1.0. For a full list of available versions, see the Directory of published versions

Table of Contents

...0 Table of Contents
...1 Home
...2 Patient Information
...3 Disease Characterization
...4 Assessment
...5 Genomics
...6 Treatments
...7 Outcomes
...8 Conformance Expectations
...9 Identifying In-Scope Patients
...10 Profile Conformance
...11 Terminology
...12 Data Dictionary
...13 Profiles
...14 Extensions
...15 Value Sets
...16 Code Systems
...17 Capability Statements
....18 Artifacts Summary
....18.1 mcode-receiver-cancer-conditions-then-patients
....18.2 mcode-receiver-patient-bundle
....18.3 mcode-receiver-patients-and-cancer-conditions
....18.4 mcode-receiver-patients-in-group
....18.5 mcode-receiver-patients-with-cancer-condition
....18.6 mcode-sender-cancer-conditions-then-patients
....18.7 mcode-sender-patient-bundle
....18.8 mcode-sender-patients-and-cancer-conditions
....18.9 mcode-sender-patients-in-group
....18.10 mcode-sender-patients-with-cancer-condition
....18.11 mcode-patient-everything
....18.12 Cancer Disease Status Profile
....18.13 Cancer Patient Profile
....18.14 Cancer-Related Medication Administration Profile
....18.15 Cancer-Related Medication Request Profile
....18.16 Cancer-Related Surgical Procedure Profile
....18.17 Cancer Stage Group Profile
....18.18 Comorbidities Profile
....18.19 ECOG Performance Status Profile
....18.20 Genomic Region Studied Profile
....18.21 Genomic Variant Profile
....18.22 Genomics Report Profile
....18.23 Human Specimen Profile
....18.24 Karnofsky Performance Status Profile
....18.25 mCODE Patient Bundle Profile
....18.26 mCODE Patient Group Profile
....18.27 Primary Cancer Condition Profile
....18.28 Radiotherapy Course Summary Profile
....18.29 Radiotherapy Volume Profile
....18.30 Secondary Cancer Condition Profile
....18.31 TNM Distant Metastases Category Profile
....18.32 TNM Primary Tumor Category Profile
....18.33 TNM Regional Nodes Category Profile
....18.34 TNM Stage Group Profile
....18.35 Tumor Profile
....18.36 Tumor Marker Test Profile
....18.37 Tumor Size Profile
....18.38 Body Structure Identifier Profile
....18.39 Body Location Qualifier Extension
....18.40 Cancer Disease Status Evidence Type Extension
....18.41 Histology-Morphology-Behavior Extension
....18.42 Laterality Qualifier Extension
....18.43 Procedure Intent Extension
....18.44 Radiotherapy Dose Delivered To Volume Extension
....18.45 Radiotherapy Modality Extension
....18.46 Radiotherapy Modality And Technique Extension
....18.47 Radiotherapy Number of Sessions Extension
....18.48 Radiotherapy Technique Extension
....18.49 Related Condition Extension
....18.50 Related Condition Absent Extension
....18.51 Treatment Termination Reason Extension
....18.52 Benign Neoplasm of Brain and CNS Disorder Value Set
....18.53 Body Location and Laterality Qualifier Value Set
....18.54 Body Location Qualifier Value Set
....18.55 Brachytherapy High Dose Rate Electronic Technique Value Set
....18.56 Brachytherapy High Dose Rate Technique Value Set
....18.57 Brachytherapy Low Dose Rate Temporary Radation Technique Value Set
....18.58 Brachytherapy Modality Value Set
....18.59 Brachytherapy Permanent Seeds Technique Value Set
....18.60 Brachytherapy Pulsed Dose Rate Technique Value Set
....18.61 Brachytherapy Radiopharmaceutical Technique Value Set
....18.62 Brachytherapy Technique Value Set
....18.63 Cancer Body Location Value Set
....18.64 Cancer Disease Status Evidence Type Value Set
....18.65 Cancer Disorder Value Set
....18.66 Cancer-Related Surgical Procedure Value Set
....18.67 Cancer Stage Group Value Set
....18.68 Cancer Staging Method Value Set
....18.69 Cancer Staging Type Value Set
....18.70 Carcinoma In-Situ Disorder Value Set
....18.71 Condition Status Trend Value Set
....18.72 Cytologic Evidence of Malignancy Value Set
....18.73 Histology Morphology Behavior Value Set
....18.74 Human Specimen Type Value Set
....18.75 Specific Diagnosis of Cancer Value Set
....18.76 Laterality Qualifier Value Set
....18.77 Melanoma In-Situ Disorder Value Set
....18.78 Primary Cancer Disorder Value Set
....18.79 Primary Malignant Neoplasm Disorder Value Set
....18.80 Procedure Intent Value Set
....18.81 Radiotherapy Modality Value Set
....18.82 Radiotherapy Technique Value Set
....18.83 Radiotherapy Treatment Location Qualifier Value Set
....18.84 Radiotherapy Treatment Location Value Set
....18.85 Radiotherapy Volume Type Value Set
....18.86 Secondary Cancer Disorder Value Set
....18.87 TNM Distant Metastases Maximum Value Set
....18.88 TNM Distant Metastases Category Value Set
....18.89 TNM Distant Metastases Staging Type Value Set
....18.90 TNM Primary Tumor Maximum Value Set
....18.91 TNM Primary Tumor Category Value Set
....18.92 TNM Primary Tumor Staging Type Value Set
....18.93 TNM Regional Nodes Maximum Value Set
....18.94 TNM Regional Nodes Category Value Set
....18.95 TNM Regional Nodes Staging Type Value Set
....18.96 TNM Stage Group Maximum Value Set
....18.97 TNM Stage Group Staging Type Value Set
....18.98 TNM Stage Group Value Set
....18.99 TNM Staging Method Value Set
....18.100 Carbon Ion Beam Technique Value Set
....18.101 Electron Beam Technique Value Set
....18.102 Teleradiotherapy Modality Value Set
....18.103 Neutron Beam Technique Value Set
....18.104 Photon Beam Technique Value Set
....18.105 Proton Beam Technique Value Set
....18.106 Teleradiotherapy Technique Value Set
....18.107 Treatment Termination Reason Value Set
....18.108 Tumor Marker Test Value Set
....18.109 Tumor Size Method Value Set
....18.110 Tumor Size Units Value Set
....18.111 Requested SNOMED Codes Code System
....18.112 TG263CM
....18.113 Search by code:in in Conditions
....18.114 Search by _id in Patients with multipleOr
....18.115 binet-stage-group-A
....18.116 bodyheight-jenny-m-2018-03-06
....18.117 bodyweight-jenny-m-2018-03-16
....18.118 bodyweight-jenny-m-2018-04-22
....18.119 cancer-disease-status-improved
....18.120 cancer-disease-status-jenny-m
....18.121 cancer-patient-adam-everyman
....18.122 cancer-patient-eve-anyperson
....18.123 cancer-patient-jenny-m
....18.124 cancer-patient-john-anyperson
....18.125 cancer-related-comorbidities-jenny-m
....18.126 cancer-related-comorbidities-john-anyperson
....18.127 cancer-related-medication-admin-cyclophosphamide-jenny-m
....18.128 cancer-related-medication-admin-doxorubicin-jenny-m
....18.129 cancer-related-medication-admin-paclitaxel-jenny-m
....18.130 cancer-related-medication-request-anastrozole-jenny-m
....18.131 cancer-related-medication-request-cisplatin
....18.132 cancer-related-medication-request-cyclophosphamide-jenny-m
....18.133 cancer-related-medication-request-doxorubicin-jenny-m
....18.134 cancer-related-medication-request-gefitinib
....18.135 cancer-related-medication-request-paclitaxel-jenny-m
....18.136 cancer-related-surgical-procedure-jenny-m
....18.137 cancer-related-surgical-procedure-lobectomy
....18.138 ecog-performance-status-fully-active
....18.139 ecog-performance-status-jenny-m
....18.140 family-member-history-aunt-jenny-m
....18.141 family-member-history-sister-jenny-m
....18.142 family-member-history-uncle-jenny-m
....18.143 genomic-region-studied-jenny-m
....18.144 genomic-region-studied-stk11
....18.145 genomic-variant-fusion
....18.146 genomic-variant-germline-deletion
....18.147 genomic-variant-jenny-m
....18.148 genomic-variant-somatic-single-nucleotide
....18.149 genomics-report-jenny-m
....18.150 genomics-report-john-anyperson
....18.151 mCODE Patient Group Example
....18.152 gx-cancer-patient-adam-anyperson
....18.153 gx-genomic-bundle-adam-anyperson
....18.154 gx-genomic-diagnostic-implication-bap1
....18.155 gx-genomic-diagnostic-implication-pof1b
....18.156 gx-genomic-diagnostic-implication-polrmt
....18.157 gx-genomic-msi
....18.158 gx-genomic-specimen-tumornormal-normal
....18.159 gx-genomic-specimen-tumornormal-tumor
....18.160 gx-genomic-therapeutic-implication-alectinib
....18.161 gx-genomic-therapeutic-implication-brigatinib
....18.162 gx-genomic-therapeutic-implication-ceritinib
....18.163 gx-genomic-therapeutic-implication-crizotinib
....18.164 gx-genomic-therapeutic-implication-lorlatinib
....18.165 gx-genomic-tmb
....18.166 gx-genomic-variant-fusion-met-alk
....18.167 gx-genomic-variant-pertinent-negative-nras-kit-braf
....18.168 gx-genomic-variant-somatic-bap1-indel
....18.169 gx-genomic-variant-somatic-cdkn2a-cnv
....18.170 gx-genomic-variant-somatic-cdkn2b-cnv
....18.171 gx-genomic-variant-somatic-kdm5d
....18.172 gx-genomic-variant-somatic-mtap
....18.173 gx-genomic-variant-somatic-mycn
....18.174 gx-genomic-variant-somatic-pof1b
....18.175 gx-genomic-variant-somatic-polrmt
....18.176 gx-genomics-report-adam-anyperson
....18.177 gx-order-tumornormal-tempus-inc
....18.178 gx-practitioner-test-pathologist
....18.179 gx-us-core-organization-tempus-inc
....18.180 gx-us-core-organization-test-institution
....18.181 human-specimen-left-breast-jenny-m
....18.182 human-specimen-lung
....18.183 jenny-m-chest-wall-lymph-nodes-treatment-volume
....18.184 jenny-m-chest-wall-treatment-volume
....18.185 john-anyperson-chf
....18.186 john-anyperson-treatment-volume
....18.187 karnofsky-performance-status-normal-activity
....18.188 lab-result-observation-hemoglobin
....18.189 mcode-patient-bundle-jenny-m
....18.190 observation-smoking-pack-years-jenny-m
....18.191 primary-cancer-condition-breast
....18.192 primary-cancer-condition-cll
....18.193 primary-cancer-condition-jenny-m
....18.194 primary-cancer-condition-nsclc
....18.195 radiotherapy-treatment-summary-chest-wall-jenny-m
....18.196 secondary-cancer-condition-brain-mets
....18.197 tnm-clinical-distant-metastases-category-cM0
....18.198 tnm-clinical-distant-metastases-category-jenny-m
....18.199 tnm-clinical-primary-tumor-category-cT3
....18.200 tnm-clinical-primary-tumor-category-jenny-m
....18.201 tnm-clinical-regional-nodes-category-cN3
....18.202 tnm-clinical-regional-nodes-category-jenny-m
....18.203 tnm-clinical-stage-group-3c
....18.204 tnm-clinical-stage-group-jenny-m
....18.205 tnm-pathologic-distant-metastases-category-jenny-m
....18.206 tnm-pathologic-primary-tumor-category-jenny-m
....18.207 tnm-pathologic-regional-nodes-category-jenny-m
....18.208 tnm-pathologic-stage-group-jenny-m
....18.209 tumor-lobular-carcinoma-left-breast
....18.210 tumor-marker-test-egf
....18.211 tumor-marker-test-er-jenny-m
....18.212 tumor-marker-test-her2-jenny-m
....18.213 tumor-marker-test-oncotype-dx-jenny-m
....18.214 tumor-marker-test-pr-jenny-m
....18.215 tumor-size-jenny-m
....18.216 tumor-size-pathology
....18.217 tumor-specimen-left-breast-jenny-m
....18.218 tumor-specimen-lobular-carcinoma-left-breast
....18.219 us-core-condition-anxiety-jenny-m
....18.220 us-core-condition-depression-jenny-m
....18.221 us-core-condition-hypertension-jenny-m
....18.222 us-core-diagnosticreport-lab-jenny-m
....18.223 us-core-observation-lab-neutrophils-jenny-m
....18.224 us-core-observation-lab-sentinel-nodes-jenny-m
....18.225 us-core-observation-lab-tumor-dcis-jenny-m
....18.226 us-core-observation-lab-tumor-grade-jenny-m
....18.227 us-core-observation-lab-tumor-invasion-jenny-m
....18.228 us-core-observation-lab-tumor-margins-jenny-m
....18.229 us-core-organization-bedrock-medicine
....18.230 us-core-organization-physician-services-inc
....18.231 us-core-practitioner-jane-radiotech
....18.232 us-core-practitioner-kyle-anydoc
....18.233 us-core-practitioner-mary-obgyn
....18.234 us-core-practitioner-nancy-oncology-nurse
....18.235 us-core-practitioner-owen-oncologist
....18.236 us-core-practitioner-peter-pathologist
....18.237 us-core-procedure-biopsy-jenny-m
....18.238 us-core-procedure-mammogram-jenny-m
....18.239 us-core-smokingstatus-jenny-m
...19 Basic Examples
...20 Extended Example
...21 Release Notes
...22 Glossary
...23 Download Specification